CAPD 3 Balance Peritoneal Dialysis Solution

Adult administration

For adults, 1.5–2.5 L should be administered into the peritoneal cavity and left for 4–8 hours before draining, repeated 3–5 times a day.

This medication is a dialysis solution for peritoneal dialysis, used to remove body waste and excess fluid through the patient's peritoneum. Patients should be cautious, as prematurely discontinuing treatment without receiving alternative renal therapies may pose a threat to life. Patients with a perforation of the diaphragm, severe abdominal burns, severe peritoneal adhesions, bleeding disorders, lactate metabolism disorders, severe electrolyte imbalance, recent abdominal surgery or inflammation should not use this medication. Additionally, patients who are mentally or physically unable to perform peritoneal dialysis should avoid administration. Patients taking digitalis preparations or suspected to have glucose metabolism disorders should regularly monitor serum potassium and blood glucose levels when using this medication. Extra caution is needed for patients who had abdominal surgery, have severe respiratory disorders, are immunocompromised, or are pregnant. Pain, bleeding, or inflammation may occur at the injection site, and symptoms like peritonitis or abdominal pain, gastrointestinal symptoms, electrolyte imbalance, and metabolic disorders may arise. Any abnormal symptoms should be reported to medical personnel immediately. During peritoneal dialysis, body weight, nutritional status, and serum electrolytes/metabolic conditions should be regularly monitored for appropriate management. This solution must be used under sterile conditions, and if the container is damaged or if the solution is cloudy or contains foreign substances, it should not be used. For children, the dosage should be adjusted, and elderly patients have a higher risk of hernia; thus, careful evaluation before dialysis is essential. In cases of overdose, side effects like dehydration, electrolyte imbalances, and hyperglycemia may occur, necessitating proper usage and management. The safety of this medication has not been established in pregnant or lactating women, so it should only be used when the benefits outweigh the risks. This medication is intended for peritoneal dialysis use only and should not be used as an injection. To prevent infections during peritoneal dialysis, manipulations should be conducted in a sterile environment, and the condition of the container must always be checked before use.

Serious side effects

Peritonitis (may be accompanied by fever), sepsis, respiratory distress, pulmonary edema, pleural effusion, edema.

Mild side effects

Abdominal pain, bleeding, peritonitis (abdominal pain, cloudy effluent sometimes accompanied by fever), inflammation around the peritoneal catheter (redness, discharge), subcutaneous edema in case of catheter damage or drainage difficulty, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal distention, hypokalemia, hyponatremia, hypercalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoproteinemia.

This medication should be stored in a sealed container to prevent air from entering and kept in a cool place below 25 degrees Celsius. It should also be kept away from freezing.

Appearance

Colorless and transparent solution divided into A solution (left) and B solution (right) in the shape of A.

Package unit

Box of 100 [1 x 1500mL, 1 x 2000mL, 1 x 2500mL, 1 x 3000mL], Box of 400 [4 x 2000mL, 4 x 2500mL, 4 x 3000mL], Box of 600 [6 x 1500mL]